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Abstract
Proteomics is the science that studies the proteome, which corresponds to the 
global expression of proteins at a given time under determined conditions. In the 
last 20 years, proteomics has emerged as a powerful tool that has allowed the study 
of proteins that are expressed in the cell under normal or altered conditions as well 
as post-translational modifications, such as phosphorylation, glycosidation, acety-
lation, and methylation, among others. In this chapter, we present the main contri-
butions of proteomics to the knowledge of Trypanosoma cruzi biology. Proteomes of 
all T. cruzi life cycle stages, secretomes/exoproteomes, post-translational modifica-
tions such as phosphorylation or acetylation and immunomes, interactomes, and 
glycomes are described. The role of proteomics in the identification of new chemo-
therapeutic targets and potential vaccine candidates will also be discussed.
Keywords: Trypanosoma cruzi, proteomics, subcellular proteomics,  
post-translational modifications, drug resistance, virulence, secretome/exoproteome
1. Introduction
The flagellate protozoan Trypanosoma cruzi is the causative agent of Chagas 
disease, an illness that affects 6–8 million people worldwide [1]. The parasite has a 
complex life cycle, which starts when the triatomines defecate in the vicinity of the 
bite, and in the infective stage, the metacyclic trypomastigote (MT) is carried into 
the wound by scraping and then penetrates across the skin and invades resident 
cells. Once in the cytosol, MTs transform into amastigotes. This proliferative stage 
multiply in the cytosol and, after various rounds of binary fission, transform into 
trypomastigotes, which are released from the cell and disseminated by the blood-
stream invading different organs, spreading the parasitic infection [2].
From a biological and biochemical point of view, T. cruzi is a genetically hetero-
geneous species with a wide variety of strains distributed in different vectors and 
with a great diversity of mammalian hosts. This high genetic variability is related to 
the variability of virulence and clinical manifestations among strains [3]. Currently, 
T. cruzi is classified into seven discrete typing units (DTUs), TcI to TcVI [4], and 
more recently, a new one named Tcbat has been included [5].
2. The proteomics and mass spectrometry
Proteomics is a discipline focused on understanding protein expression in bio-
logical samples and the possible comprehension of the complex physiological and 
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pathological events using different methods to identify and characterize proteins. 
Thus, proteomics is the study of the proteome, which corresponds to the global pat-
terns of proteins that determine cell expression under a determinate condition [6].
From 1997, when the first paper on the proteome was published [7], proteomics 
studies have become an invaluable tool not only for the study of the global cell 
expression of proteins (the proteome) but also for the dissection of specific 
processes in cell biology and biochemistry, such as the study of proteins that are 
expressed in organelles and post-translational modifications [8, 9]. Moreover, by 
combining proteomics analysis and bioinformatics tools, researchers can report 
much broader projections, including the identification of new chemotherapeutic 
targets, new vaccine candidates, new tumor markers with prognostic or diagnostic 
value [10], and the study of secretomes and immunonomes, among others [11]. 
Thus, a current PubMed search with the keyword “proteomic” delivers 96,688 
published papers.
Initially, Edman sequencing was used, and this method was replaced by 
mass spectrometry (MS). MS allows the separation of different isotopes, which 
is possible due to the use of soft ionization procedures, such as matrix-assisted 
laser desorption/ionization (MALDI) [12] and the electrospray ionization 
method (ESI) [13]. In both cases, the analytes (peptides) are ionized from the solid 
phase (MALDI) or liquid phase (ESI) into the gas phase. Then, liquid chromatog-
raphy (LC) systems can be directly interfaced to mass spectrophotometers. LC 
tandem mass spectrometry (LC-MS/MS) has been applied to proteomics to separate 
peptides, and MS/MS records the intact peptides (full MS) before one precursor 
ion is selected and fragmented. This fragmentation is always induced in a collision 
cell by nitrogen or argon. Then, fragments are recorded in an MS/MS spectrum, 
and this fragmentation pattern reveals a specific mass for each amino acid from the 
peptide [6]. In summary, the amino acids present in the peptide can be determined, 
as well as the peptide sequence, and finally, the protein containing this peptide is 
identified.
In kinetoplastids like T. cruzi, all protein-encoding genes are organized in large 
polycistronic transcription units that produce polycistronic precursor RNAs that are 
then processed to monocistronic mRNAs by the mechanism of trans-splicing [14]. 
Then, translation of specific mRNAs and/or the stability control regulate the gene 
expression [15]. Furthermore, post-translational modifications perform a key func-
tion in order to modulate the T. cruzi protein function. For these reasons, in recent 
years, proteomics has had a crucial role in evaluating protein expression levels in 
different T. cruzi stages or following specific treatments with drugs, inhibitors, or 
natural products, and thus, proteomics studies have been transformed in an invalu-
able tool to reveal adaptive changes in this protozoan [16].
3. The T. cruzi proteome
A proteomic analysis of the human pathogen T. cruzi using two-dimensional 
electrophoresis (2-DE) was initially reported by Paba et al. [17]. A T. cruzi com-
parative proteome analysis of different stages was performed. This study showed 
that few proteins displayed significant differential expression among the three 
developmental T. cruzi stages. Using matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry peptide mass fingerprinting, the 
researchers identified 26 proteins. Among these, 19 different proteins were identi-
fied, mainly heat shock proteins (HSP; chaperones, HSP 60, HSP 70, and HSP 90), 
elongation factors, glycolytic pathway enzymes (enolase, pyruvate kinase, and 
2,3 bisphosphoglycerate mutase), and structural proteins (KMP 11, tubulin, and 
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paraflagellar rod components). In addition, the same researchers reported a com-
parative proteome analysis of T. cruzi developmental stages. In this study, isotope-
coded affinity tag technology (ICAT) associated with liquid chromatography-mass 
spectrometry peptide sequencing (LC-MS/MS) was used. High-confidence 
sequence information and expression levels for 41 T. cruzi polypeptides, includ-
ing metabolic enzymes, paraflagellar rod components, tubulins, and heat shock 
proteins, were reported. Twenty-nine proteins displayed similar expression levels 
in trypomastigotes as well as amastigotes, nine proteins displayed higher levels in 
trypomastigotes than amastigotes, and three proteins showed higher expression in 
amastigotes than trypomastigotes [18].
In addition, Parodi-Talice et al. [16] described a standardized and reproducible 
protocol for analyzing T. cruzi proteins by 2-DE, which generated protein reference 
maps of this parasite. In this report, tubulins, HSP, and prostaglandin F2α synthase 
were three of the most abundant proteins reported in T. cruzi.
A proteomic analysis of all T. cruzi stages was performed. Peptidic sequences 
from 2784 proteins in 1168 protein groups from the annotated T. cruzi genome were 
reported in all parasite stages. Protein products were identified from >1000 genes 
annotated as “hypothetical” in the parasite genome, including integrants of the 
mucin-associated surface proteins (MASP). The four parasite stages appear to use 
distinct energy sources, including histidine for stages present in the insect vectors 
and fatty acids by intracellular amastigotes [19]. In contrast, a study that identified 
basic proteins reported different enzymes related to amino acid metabolism in 
epimastigotes, whereas trans-sialidases and protein paraflagellar rods were found 
specifically in trypomastigotes [20]. Another proteomics study of T. cruzi trypo-
mastigotes identified 1448 nonredundant proteins, 14% of which corresponded 
to surface proteins, and the majority were anchored via glycophosphatidylinositol 
(GPI) and related to parasite virulence [21]. According to these authors, the high 
diversity of expressed proteins on the trypomastigote surface could have implica-
tions for both invasion and immune evasion strategies. A comparison of the cell 
surface proteomes from different T. cruzi stages revealed that some enzymes 
are stage-specific, although the majority were present in more than one stage. 
Bioinformatics analysis showed that most of the identified proteins were derived 
from the membrane and were involved in cell invasion, adhesion, cell signaling, 
and host immune response modulation [22]. However, the biological role of these 
proteins was not experimentally demonstrated.
The blood trypomastigote (BT) proteome has also been described [23]. In a 
shotgun analysis, 17,394 peptides were reported, corresponding to 7514 proteins of 
which 5901 corresponded to T. cruzi. Trans-sialidases (TS), bioenergetics-related 
enzymes, chaperones, and cytoskeletal proteins were found among the top scoring 
proteins. Gene ontology (GO) studies showed that all T. cruzi compartments were 
evaluated and the most part of proteins were engaged in metabolic processes and/or 
presented catalytic functions. A comparative study among BT and tissue-culture-
derived trypomastigote (TCDT) or metacyclic trypomastigote (MT) proteomic 
profiles identified 2202 proteins uniquely reported in the BTs. These unique pro-
teins were related to (a) surface proteins, (b) the nonclassical secretion pathway, 
(c) cytoskeletal dynamics, (d) the cell cycle and transcription, (e) proteolysis, 
(f) redox metabolism, (g) biosynthetic pathways, (h) bioenergetics, (i) protein 
folding, (j) cell signaling, (k) vesicular traffic, (l) DNA repair, and (m) cell death 
[23]. The Brunoro paper identified many proteins belonging to different metabolic 
parasite pathways and functions that were exclusive to BTs and provided a valuable 
data set for a better biological understanding of this parasite stage.
The T. cruzi cell surface is covered by a dense layer of GPI-anchored molecules. 
These molecules are involved in a variety of interactions between the parasite and 
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its vertebrate and invertebrate hosts. GPI-anchored rich fractions and other T. cruzi 
membrane proteins were obtained from epimastigotes (EPIs) and MTs and then 
submitted to two-dimensional liquid chromatography coupled to tandem mass 
spectrometry (2D-LC-MS/MS). A total of 98 MT proteins and 280 EPI proteins 
were identified. Of those, approximately 65% (n = 245) had predicted lipid post-
translational modification sites (i.e., GPI-anchor, myristoylation, or prenylation), 
signal-anchor sequences, or transmembrane domains that could explain their 
solubility in detergent solution. This report showed that MTs, but not EPIs, express 
a large repertoire of surface glycoproteins, such as GP90 and GP82, which are 
involved in host cell adhesion and invasion. Taken together, these results showed 
that T. cruzi displays stage-specific protein profiles that are related to the biology of 
each T. cruzi stage [24].
A map of soluble proteins from epimastigotes of T. cruzi CL Brener was generated 
using 2-DE combined with MS. The analysis showed that several proteins, such as 
tubulin and heat shock proteins, were found in multiple isoforms. The enzyme argi-
nine kinase was also found. This enzyme is absent in mammalian cells and, accord-
ing to the authors, could represent a potential new chemotherapeutic target [25].
Using conditions optimized for the 6–11 pH range, researchers compared the 
proteomes of TCDTs and extracellular amastigote-like parasites by MALDI-TOF/
TOF. The alkaline 2-DE gels from TCDTs and extracellular amastigotes showed that 
proteins with a pI over 7.0 were very well depicted (= 65% of proteins detected). 
Furthermore, the differences in protein expression among the human-hosted 
T. cruzi stages were in agreement with former proteomics reports and were related 
to the biological properties of each parasite stage [26].
4. The T. cruzi secretome/exoproteome
Adhesion and invasion are the first stages of interaction between an obligate 
intracellular pathogen and its host cell. This process involves cell surface molecules 
and secreted molecules. Then, the molecules that are released from pathogens may 
play a critical role during the establishment of infection, especially in immunomod-
ulation or immune evasion, as well as in migration across host tissues, cell adhesion, 
cell-cell communication, differentiation, proliferation, and morphogenesis [27, 28].
The term secretome was first introduced in a bioinformatics survey of proteins 
secreted by Bacillus subtilis [29]. The authors defined the secretome as the subset of 
the proteome that is secreted, in addition to the components of cellular machinery 
used for protein secretion. However, these released proteins are not only secreted 
proteins but also proteins that arise from other export mechanisms. Thus, the best 
term to describe the protein content found in the extracellular proximity of a given 
biological system is the “exoproteome” [30].
According to [31], T. cruzi releases proteins associated with two types of vesicles. 
The large vesicles (LVs), named ectosomes, arise from the plasma membrane, and 
small vesicles (SVs), similar to exosomes, are released by the flagellar pocket. A 
third fraction was enriched in soluble proteins and was not associated with extracel-
lular vesicles (EVs) [31]. Label-free quantitative proteomics analysis showed the 
presence of proteins associated with metabolism, signaling, packaging of nucleic 
acids, parasite survival, and virulence [31].
The T. cruzi exoproteome of TCDTs (Y strain) was recently character-
ized. NanoLC-MS/MS analysis resulted in the identification of 540 proteins. 
Bioinformatics analysis predicted most identified proteins as secreted, predomi-
nantly by nonclassical pathways, and suggested that these proteins are involved in 
host cell interaction. Some proteins possess predicted GPI-anchor signals; these 
5
Role of Proteomics in the Study of Trypanosoma cruzi Biology
DOI: http://dx.doi.org/10.5772/intechopen.85323
proteins are mostly TS, MASP, and surface glycoproteins. The existence of various 
related proteins to similar functions in the exoproteome likely reflects this parasite’s 
enhanced mechanisms for adhesion, invasion, and internalization of different host 
cell types and immune evasion [32].
Considering that Chagas disease is a chronic infection in which amastigote forms 
remain for a long time, the T. cruzi laboratory examination using direct observation 
is tricky, and although antibody detection tests are sensitive, they may give false-
positive results. The implementation of novel fast assays aimed for the identifica-
tion of excretory/secretory parasite-derived molecules in serum would be a useful 
contribution in the diagnosis of human T. cruzi infection. Brossas and coworkers 
[33] investigated the proteins secreted by T. cruzi using MS analyses of conditioned 
culture media devoid of serum, collected during the emergence of trypomastigotes 
from infected Vero cells. Indeed, the secretomes of two T. cruzi strains from DTU 
TcVI (VD and CL Brener) were compared. This study led to the identification of 
591 T. cruzi proteins. Three hundred sixty-three proteins were common to both 
strains, and most belong to different multigenic super families (e.g., TcS, GP63, 
MASP, and DGF1). Finally, a report of 94 secreted proteins, present in both DTU 
TcVI strains that do not correspond to the members of multigene families, was also 
established. This paper offers the first comparative study of the secretomes from 
two different T. cruzi strains of DTU TcVI. Then, Brossas and coworkers’ papers 
identified a subset of common secreted proteins that could have a potential role as 
serum biomarkers for T. cruzi infection [33].
A novel family of T. cruzi surface membrane proteins (TcSMPs), which are con-
served among different T. cruzi lineages and have orthologs in other Trypanosoma 
species, was described. Several lines of evidence suggest that TcSMP is a membrane-
spanning protein located at the cellular surface and is also released into the extra-
cellular milieu. TcSMP displayed a signal anchor and a C-terminal hydrophobic 
sequence predicted to be a transmembrane domain. In addition, proteomic TcSMP 
peptides previously found in a membrane-enriched fraction were identified in 
membrane vesicles as well as in soluble forms in the T. cruzi secretome. TcSMP 
proteins were also located intracellularly, likely associated with membrane-bound 
structures. These proteins were shown to inhibit metacyclic trypomastigote entry 
into host cells. TcSMPs could bind to mammalian cells and trigger Ca2+ signaling 
and lysosome exocytosis. This evidence strongly suggests the involvement of these 
proteins in parasite invasion [34].
5. T. cruzi subcellular proteomics
A combination of MS-based proteomics methods and traditional biochemical 
cell fractionation protocols had been used to characterize subcellular organization. 
The protein contents of specific subcellular compartments can thus be identified 
following specific enrichment strategies that concentrate and enrich organelles and 
subcompartments of the cell [8].
T. cruzi reservosomes show concentrated proteins and lipids obtained from 
medium together with the main proteolytic enzymes originating from the secretory 
pathway, being at the same time a storage organelle and the main site of protein 
degradation and endpoint of the parasite endocytic pathway. By cell fractionation 
and LC-MS/MS, the EPI reservosome-resident proteins were identified in a total 
of 709 T. cruzi-specific proteins. Among these, 456 had predicted functions and 
253 were described as hypothetical proteins. The existence of a high number of 
previously reported proteins was confirmed. In addition, new different classes 
of proteins were reported. Among them, transport proteins, proton pumps, and 
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enzymes were also identified. According to the authors, the definition of the 
reservosome protein profile could be a good tool to assess the molecular signatures, 
identify molecular markers, and understand the relationship with different parasite 
organelles [35].
The EPI transition from the exponential growth phase to the stationary phase is 
a key step that recapitulates the early molecular events of T. cruzi metacyclogenesis, 
opening new possibilities for understanding this process. Thus, a quantitative shot-
gun proteomics study of the T. cruzi EPIs in the exponential and stationary growth 
phases was performed. More than 3000 proteins were identified and quantified, 
stressing the regulation of proteins engaged in various subcellular compartments. 
Ribosomal proteins were positively regulated in the exponential phase, in agree-
ment with the high proliferative rate of this growth phase. Autophagy-related 
proteins were positively regulated in the stationary growth phase, showing the 
beginning of the metacyclogenesis. Otherwise, this paper reported the regulation 
of N-terminally acetylated proteins during growth phase transitioning, adding a 
new layer of regulation to this process. Thus, this paper reported a proteome-wide 
rewiring during T. cruzi differentiation from the EPIs’ proliferative exponential 
phase to the stationary growth phase, which is the step before cell transformation 
into the MT stage [36].
In the eukaryotic cell, chromatin-associated proteins are key regulators of many 
important processes. By high-resolution MS, the T. cruzi chromatin proteome was 
investigated using three different protocols and comparing it between two parasite 
stages, EPIs and TCDTs. More than 2000 proteins were identified and quantified 
both in chromatin and nonchromatin extracts. In addition to histones and other 
known nuclear proteins, trypanosome chromatin also contains metabolic proteins 
(mainly from carbohydrate pathways), cytoskeleton components, and many other 
proteins with unknown functions. In addition, EPIs and TCDTs also differ greatly 
regarding their chromatin-associated factor composition and amount. Although 
the nucleosome content was the same for both stages, the remaining proteins were 
rarely detected in TCDTs, suggesting that they have naked chromatin. Proteins 
associated with DNA proliferation, such as proliferation cell nuclear antigen 
(PCNA), replication protein A (RPA), and DNA topoisomerases, were exclusively 
found in the chromatin of EPIs. However, TCDTs showed an enrichment of a his-
tone H2B variant. Moreover, nearly 20% of the EPIs’ chromatin-associated proteins 
were expressed in TCDTs but were placed in the nonchromatin space. Several types 
of proteins, including phosphatases and a Ran-binding protein, that may be trans-
ported among chromatin and the nonchromatin space during differentiation were 
also identified. These results indicated that the replicative state in trypanosomes 
involves an increase in chromatin-associated protein content. Given that trypano-
somes are early-branching organisms, these data could enhance our understanding 
of chromatin-associated processes in other cell types [37].
T. cruzi proliferation displays unique features, such as the absence of chromo-
some condensation and closed mitosis. Thus, T. cruzi epimastigotes were lysed, and 
the nuclear fraction was isolated to study the proteome by LC-MS/MS. A total of 
864 proteins were identified, of which 272 were annotated as putative uncharacter-
ized proteins and 275 had not been previously reported in the T. cruzi proteome. 
Bioinformatics analysis using the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) was carried out, and proteins were grouped into 
nuclear proteins in 65 gene clusters, wherein the clusters with the highest enrich-
ment scores harbored members with chromatin organization and DNA-binding 
functions [38].
Contractile vacuole complexes are critical components of cell volume regulation 
and have been shown to have other functional roles in several free-living protists. 
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However, very little was known about the functions on T. cruzi. A proteomics and 
bioinformatics approach to identify proteins localized to the contractile vacuole was 
performed using the T. cruzi epimastigote-enriched fraction of contractile vacuoles, 
which was analyzed by one-dimensional gel electrophoresis and LC-MS/MS. A total 
of 109 newly detected proteins were identified, including at least 39 members of the 
dispersed gene family 1 (DGF-1). This observation suggested that many members 
of this family are simultaneously expressed in EPIs. In addition, several homologs 
with known localizations in contractile vacuoles of other organisms were selected. 
GFP-fusion proteins or specific antibodies were used to determine the localiza-
tion of each protein. Six of these putative proteins (Rab11, Rab32, AP180, ATPase 
subunit B, VAMP1, and phosphate transporter) were mostly located in the vacuole 
bladder. However, TcSNARE2.1, TcSNARE2.2, and calmodulin were located in the 
spongiome. Calmodulin was a cytoplasmic protein. These observations confirmed 
the usefulness of merged subcellular fractionation, proteomics assays, and bioin-
formatics methods in order to know the location of organellar proteins that could be 
hard to identify when global proteomic approaches are used [39].
Several lines of evidence suggest that the translational system in trypanosomatids 
shows important differences compared to those of other eukaryotes. A careful data 
mining quest for ribosomal protein genes in the T. cruzi genome database coupled 
with MS of isolated T. cruzi ribosomes was performed. The findings suggested that 
T. cruzi ribosomal proteins have around 50% sequence identity to yeast proteins. In 
addition, some trypanosomal proteins were longer than yeast proteins because of the 
existence of many N- or C-terminal extensions, which are unique to trypanosoma-
tids. In detail, L19 and S21 have shown C-terminal extensions of 168 and 164 amino 
acids, respectively. Even more, two 60S subunit proteins that had not been formerly 
found in the T. cruzi whole proteome, namely, L22 and L42, were detected [40].
6. Parasite biology and reversible post-translational modifications
In eukaryotes, histones are well-conserved proteins that form the basic structure 
of chromatin and undergo several post-translational modifications, which are 
important for the control of transcription, replication, DNA damage repair, and 
chromosome condensation [41].
The processes by which T. cruzi acquires infectivity and survives in different 
hosts involve rapid adaptations to new environments and tight regulation of gene 
expression, mainly post-transcriptionally. Nevertheless, the chromatin structure/
organization of trypanosomatids is similar to that of other eukaryotes, includ-
ing histone variants and post-translational modifications. Evidence suggests that 
epigenetic mechanisms also play an important role in the parasite, indicating that 
new epigenetic targets can be used for chemotherapeutic intervention. From this 
perspective, MS-based large-scale proteomics has been used to identify T. cruzi 
post-transcriptional modifications in T. cruzi canonical and variant histones. A 
total of 13 distinct modification types were identified, including 9 newly described 
chemical modifications for trypanosomatids, which included novel and unusual 
modifications, such as alternative lysine acylations, serine/threonine acetylation, 
and N-terminal methylation. In the same way, two hundred conserved and unique 
post-transcriptional sites in the tails and globular regions of all canonical and vari-
ant histones were identified. These results provided the first comprehensive map of 
T. cruzi histone marks and provided new evidence that allowed us to gain a deeper 
understanding of the epigenetic mechanisms that operate in T. cruzi. This report 
could provide information to identify potential candidates for the development of 
new epigenetic drugs [42].
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In trypanosomatids such as T. cruzi, the regulation of gene expression is 
mostly post-transcriptional. The stability of mRNA and the possibility to accede 
to polysomes are believed to be strongly regulated, enabling T. cruzi to accom-
modate to various environmental situations that occur through its life cycle. 
Post-transcriptional regulation needs the association among mRNAs and specific 
proteins to shaping the complexes named ribonucleoproteins (mRNP). The 
dynamic association among proteins and mRNAs was studied through poly(T) 
beads to purify and characterize proteins and protein complexes linked to poly-A+ 
mRNAs. The protein contents of these fractions were studied by LC-MS/MS. A 
number of 542 protein components of the mRNP complexes associated with 
mRNAs were detected. Among them, 24 of the retrieved proteins were common to 
all fractions, whereas others were only found in an individual fraction: EPI poly-
somal (0.37%) and post-polysomal (2.95%) fractions and stress polysomal (13.8%) 
and post-polysomal (40.78%) fractions. This proteomic approach provided the first 
insight into the composition and dynamics of T. cruzi mRNPs [43].
Protein acetylation is also a post-translational modification that regulates several 
cellular pathways. Using proteomics, researchers identified 389 ε-lysine-acetylated 
sites in 235 proteins in T. cruzi epimastigotes. Lysine-acetylated protein sites were 
enriched in enzymes involved in oxidation/reduction balance, which is required for 
parasite survival in the host. These observations provide evidence that in T. cruzi, 
protein acetylation participates in the differential regulation of several cellular 
pathways and helps elucidate the mechanisms involved in parasite infection and 
survival [44].
In early-branched organisms, histones appear to be less conserved and contain 
alternative sites for modifications, which could reveal evolutionary unique func-
tions of histone modifications in gene expression and other chromatin-based pro-
cesses. Using high-resolution MS, researchers studied the T. cruzi trypomastigote 
and epimastigote histone post-translational modifications. A total of 44 new modi-
fications were detected: 18 acetylations, 7 monomethylations, 7 dimethylations, 
7 trimethylations, and 4 phosphorylations. Epimastigotes contained more histone 
modifications than trypomastigotes. Acetylations of lysines at the C-terminus 
of histone H2A and methylations of lysine 23 of histone H3 were reported to be 
enriched in MT or TCDT. Contrasting with that, protein phosphorylation at serine 
23 of H2B and methylation of lysine 76 of histone H3 predominated in epimasti-
gotes. In parasites undergoing mitosis and cytokinesis, the existence of one or two 
methylations in lysine 76 was reported. These observations helped reveal the role of 
histone modifications in gene expression control and cell cycle regulation in T. cruzi 
[45]. However, epigenetic events, such as histone acetylation, affected DNA topol-
ogy, replication, and gene expression. Histone deacetylases are involved in chroma-
tin compaction and post-translational modifications of cytoplasmic proteins, such 
as tubulin. Given these facts, histone deacetylase inhibitors, such as trichostatin A, 
were evaluated by de Oliveira Santos and coworkers to determine their effects on  
T. cruzi epimastigote cell proliferation, viability, cell cycle, and ultrastructure, as 
well as on histone acetylation and tubulin expression. A quantitative proteomics 
study showed an increase in histone acetylation after trichostatin A treatment, 
suggesting that deacetylase inhibitors may represent excellent tools for elucidating 
trypanosomatid cell biology [46].
Protein N-myristoylation is catalyzed by N-myristoyltransferase (NMT), 
an essential and potential drug target in T. cruzi. Roberts and Fairlamb used a 
combination of label-free and stable isotope labeling of cells in culture (SILAC)-
based proteomics approaches when parasites were treated with or without the 
N-myristoyltransferase inhibitor DDD85646. A total of 56 proteins present in 
at least two out of the three experimental studies were identified. Among these, 
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6 were probably to be false positives, with the remainder 50 starting with the 
amino acids MG at the N-terminus in one or more of the T. cruzi genomes. The 
greater part of these were proteins of unknown function (32), with the remaining 
(18) involved in a different spectrum of key cellular and metabolic roles, such 
as intracellular transport, cell signaling, and protein turnover. In conclusion, 
the results showed that 0.43–0.46% of the T. cruzi proteome corresponded to 
N-myristoylated proteins, slightly lower than that reported in other eukaryotic 
organisms (0.5–1.7%) [47].
Glycoproteins are very attractive therapeutic candidate targets because they 
mediate key processes during the T. cruzi life cycle, such as cellular recognition, host 
cell invasion and adhesion, and immune evasion. Using subcellular fractionation, 
lectin affinity, and SILAC, Atwood et al. [48] conducted a T. cruzi trypomastigote 
glycoproteomics analysis, which described the identification of organelles and cell 
surface N-linked glycoproteins of T. cruzi. These researchers identified 36 glycosyl-
ation sites on 35 glycopeptides that mapped to 29 glycoproteins. They also presented 
the first evidence for 11 T. cruzi-specific glycoproteins and provided experimental 
data indicating that the MASP and dispersed gene family (DGF-1) were post-
translationally modified by N-linked glycans. In another study using lectin-based 
and hydrophilic interaction liquid chromatography followed by high-resolution 
LC-MS/MS, a comprehensive glycoproteomics analysis was performed in T. cruzi 
epimastigotes and trypomastigotes. After treatment with glycanases, a number 
of 1306 N-glycosylation sites in NxS/T/C motifs were reported from 690 T. cruzi 
glycosylated proteins. Among them, 170 and 334 glycoproteins were solely detected 
in EPI and trypomastigotes, respectively. In addition, global site-specific charac-
terization of the N- and O-linked glycan heterogeneity in the two T. cruzi life stages 
was reached by intact glycopeptide methods, detecting 144/466 unique N-linked 
and 10/97 unique O-linked intact glycopeptides in epimastigotes/trypomastigotes, 
respectively. Thus, T. cruzi displays a pattern of stage-specific glycoprotein expres-
sion that may be the result of parasite interactions with vertebrate and invertebrate 
hosts during its life cycle [49].
In eukaryotic cells, SUMOylation is an important protein post-translational 
modification. The C-terminus of proteolytically activated small ubiquitin-like 
modifier (SUMO) is covalently bound to a lysine residue of the target protein by 
an isopeptide bond through a pathway that involves an E1-activating enzyme, an 
E2-conjugating enzyme, and a transfer to the target, in occasions with the support 
of a protein ligase [50]. The modification is reversed by a protease, which is also 
responsible for SUMO ripening. Several proteins have been described as SUMO 
targets and were shown to participate in the regulation of cell cycle progression, 
transcription, translation, ubiquitination, and DNA repair [50]. Orthologous 
genes corresponding to the SUMOylation pathway have been reported in T. cruzi. 
Furthermore, the SUMOylation system appears to be functionally active in the 
parasite. An immunofluorescence analysis showed that T. cruzi SUMO (TcSUMO) 
was predominantly found in the nucleus. To identify SUMOylation targets and 
further elucidate their physiological roles, researchers generated transfectant 
T. cruzi epimastigote lines expressing a double-tagged T. cruzi SUMO, and 
SUMOylated proteins were enriched by tandem affinity chromatography. By 
two-dimensional LC-MS/MS, a total of 236 proteins with different biological roles 
were reported as possible T. cruzi SUMO targets. Among these, metacaspase-3 was 
confirmed as a bona fide SUMOylation substrate by a biochemical approaches. 
The application of proteomics methods in many different biological systems has 
allowed to know that orthologs of putative T. cruzi SUMOylated proteins are 
equally modified, suggesting that conserved mechanisms could operate for protein 
SUMOylation [51].
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For the role of phosphorylation, kinase inhibitors have been suggested as novel 
antiparasitic agents. However, a fundamental understanding of the cell signaling 
pathways requires a detailed analysis of the involved phosphorylated proteins. 
A MS-based phosphoproteomic map of T. cruzi epimastigotes was performed by 
LC-MS/MS, dual-stage fragmentation, and multistage activation method. A total of 
237 phosphorylated peptides from 119 different proteins were identified. Moreover, 
220 phosphorylation sites were unequivocally mapped: 148 on serine, 57 on threo-
nine, and 8 on tyrosine. Even more, immunoprecipitation and immunoblot assays 
reported the existence of at least seven tyrosine-phosphorylated proteins in T. cruzi. 
The phosphorylated proteins were submitted to GO, InterPro, and BLAST scan 
and classified according to their roles in cell structure, motility, cellular transport, 
metabolic pathways, pathogenesis, DNA/RNA/protein turnover, and signaling. 
These phosphoproteomic information provided novel perspectives into T. cruzi 
phosphorylation pathways and the potential roles of the identified phosphoproteins 
in T. cruzi biology and reinforced the idea that kinases are parasite drug targets [52].
Furthermore, a phosphoproteomic approach was performed to determine the 
role of transforming growth factor beta (TGF-β) in T. cruzi biology. Then, EPI  
(Y strain) was incubated with TGF-β for 1, 5, 30, and 60 min, which promoted remod-
eling of the parasite phosphorylation network and protein expression pattern. To 
identify parasite proteins involved in the TGF-β response, researchers performed 
2-DE and MS. The modified proteins were engaged in many parasite functions, such 
as proteolysis, metabolism, heat shock response, cytoskeleton arrangement, oxida-
tive stress regulation, translation, and signal transduction. After TGF-β treatment, 
a number of 75 protein spots were found to be positively or negatively regulated 
more than twofold. Among these, 42 were detected by MS, highlighting, among 
these, cruzipain, the main T. cruzi papain-like cysteine protease. In these experi-
ments, TGF-β addition favored epimastigote proliferation, corroborating 2-DE data 
in which proteins previously described to be involved in this process were positively 
stimulated by TGF-β [53].
The MT proteome, which showed differential expression of some proteins 
during metacyclogenesis [54], has also been determined. Metacyclogenesis is the 
process by which T. cruzi epimastigotes differentiate into metacyclic trypomas-
tigotes and acquire the ability to infect cells and resist complement lysis. This 
process obviously requires the expression of a new set of proteins associated 
with parasite virulence. This critical step in parasite biology was first studied 
by Parodi-Talice and coworkers [55] who analyzed the process by 2-DE coupled 
to MALDI-TOF MS. A large proportion of unique proteins expressed during 
metacyclogenesis were observed. Interestingly, 50% of the spots were found to 
differ between epimastigotes and trypomastigotes. The study provided a 2D map 
of MT. Sixty-six protein spots were successfully identified, corresponding to 43 
different proteins. The expression profiles allowed protein identification during 
metacyclogenesis and categorize the proteins into three groups in accordance to 
their maximal level of expression. Various isoforms for a number of proteins, 
some of them displaying differential expression during metacyclogenesis, were 
detected. These information suggested that post-translational modifications may 
be an essential component of the parasite’s biological program to regulate gene 
expression during metacyclogenesis. The Parodi-Talice and coworkers’ paper 
contributed to the identification of relevant proteins implicated in the metacy-
clogenesis process, providing relevant information about the pathways involved 
in T. cruzi epimastigote differentiation into MTs [55]. However, a quantitative 
MS-based proteomics study of T. cruzi metacyclogenesis was performed, and 
almost 3000 proteins expressed during the process were quantified. Relevant 
proteins and pathways involved in the parasite’s differentiation and infectivity 
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acquisition were identified, opening new perspectives for further studies that 
could lead to the identification of new chemotherapeutics targets [54].
Studies of the T. cruzi phosphoproteome and the nuclear subproteome were also 
performed [56], and the results showed that the T. cruzi nuclear subproteome was 
composed of several members of the HSP family and members of the “retrotrans-
poson hot spot” (RHS) protein family as reported by De Castro Moreira Dos Santos 
et al. (2015).
The differentiation from trypomastigotes into amastigotes, called amastigo-
genesis, has also been studied in vitro by incubating TCDTs in acidic DMEM to 
perform a comprehensive quantitative proteomics and phosphoproteomics analysis 
of T. cruzi amastigogenesis. Regulated proteins and pathways involved in coordinat-
ing amastigogenesis were also identified, indicating that a significant proportion of 
the regulated proteins were membrane proteins. The authors further reported that 
modulated phosphorylation events coordinated by protein kinases and phospha-
tases are involved in signaling pathways and were triggers after incubation in acidic 
medium [22].
One of the least studied differentiation processes is the passage of infective 
trypomastigotes to epimastigotes, termed epimastigogenesis [57]. To resolve this 
issue, researchers established an in vitro and in vivo model for epimastigogen-
esis, enabling the characterization of a new infective morphological stage called 
“recently differentiated epimastigotes.” This stage was infective and resistant to 
complement-mediated lysis both in vitro and in vivo. Shotgun proteomics of all 
T. cruzi stages revealed that several proteins were upregulated only in recently 
differentiated epimastigotes (including ERO1, multidrug resistance protein E and 
ABC transporters). This evidence suggests a role for these proteins in complement-
system resistance, as previously observed for other organisms [58, 59]. As indi-
cated by the proteomics analysis, this stage contains a minimal and distinct set of 
molecules required for in vitro and in vivo infectivity, suggesting a putative role of 
epimastigotes in T. cruzi infection of mammalian cells [60].
A validated, constraint-based model of the core metabolism of T. cruzi strain CL 
Brener was carried out. The model includes 4 compartments (extracellular space, 
cytosol, mitochondrion, glycosome), 51 transport reactions, and 93 metabolic 
reactions covering carbohydrates, amino acids, and energy metabolism. In addi-
tion, several replicate high-throughput proteomic data sets were used to specifically 
examine the metabolism of T. cruzi epimastigotes. This paper shows the usefulness 
of constraint-based models for incorporating several sources of information (e.g., 
genomics, primary biochemical literature, proteomics) to build testable hypotheses. 
This model constitutes and focuses on the systematic analysis of T. cruzi metabo-
lism under a broad spectrum of conditions and disturbances and should possibly 
contribute to identify new drug targets [61].
T. cruzi is always subjected to sudden temperature shifts during its life cycle. 
The adaptive capacity to these changes is critical for parasite survival, reproduc-
tion, and transmission. These changes may modify the profile of protein expression 
that participates in homeostasis during the course of stress treatment. Thus, the 
proteome of T. cruzi EPI exposed to heat shock was analyzed by 2-DE followed by 
MS for protein identification. A total number of 24 spots differing in abundance 
were reported. Of the 24 modified spots, 19 showed a higher intensity and 5 
showed a smaller intensity in relation to the control. Various functional categories 
of the reported proteins were determined: metabolism, cell defense, hypothetical 
proteins, protein fate, protein synthesis, cellular transport, and cell cycle. Proteins 
engaged in the interaction with the cellular environment were reported too [62].
A proteomics analysis of an organellar cell fraction from T. cruzi CL Brener 
epimastigotes was reported by Ferella et al. [63]. A total number of 396 proteins were 
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determined by LC-MS/MS. Among these, 138 were reported as hypothetical in the 
genome databases, and the remainder was allocated to many metabolic and biosyn-
thetic pathways, transport, and structural functions. Comparative studies with an 
entire cell proteome are made possible to validate the expression of 173 additional 
proteins. Among these, 38 proteins previously detected in other stages were not 
found in the only large-scale study of the total EPI proteome. A chosen set of identi-
fied proteins was further studied in order to know their gene copy number, sequence 
variation, transmembrane domains, and targeting signals. The genes were cloned, 
and the recombinant proteins were expressed with a c-myc epitope tag in T. cruzi 
EPIs. Immunofluorescence microscopy showed the location of these proteins in dif-
ferent cellular compartments, such as the ER, acidocalcisome, mitochondrion, and 
putative cytoplasmic transport or delivery vesicles. These pieces of evidences rein-
force the idea that the use of enriched subcellular fractions allowed the identification 
of T. cruzi proteins that were unnoticed by whole cell proteomics approaches [63].
7. Proteomics in experimental chemotherapy and drug resistance
Chagas disease chemotherapy is based mainly on benznidazole (Bz) and 
nifurtimox (Nx), developed more than four decades ago, which are very efficient 
nitroderivatives against the acute stage but present limited efficacy during the 
chronic phase. In fact, both are far from ideal due to substantial secondary side 
effects, limited efficacy against different parasite isolates, the need for long-term 
therapy, and their well-known poor activity in the late chronic phase. Thus, iden-
tification of improved drugs to treat T. cruzi-infected people is urgently needed. 
Even though many different kinds of natural and synthetic compounds have been 
described to have in vitro and in vivo activity against T. cruzi, since the introduction 
of Bz and Nf, only scarce chemotherapeutic compounds, such as allopurinol and 
some sterol inhibitors, have moved to clinical assays.
The proteome of two T. cruzi strains after piplartine treatment was reported 
[64]. Considerable changes in the expression of enzymes involved in parasite 
protection against oxidative stress, such as tryparedoxin peroxidase (TXNPx) 
and methionine sulfoxide reductase (MSR), were observed in both strains. These 
findings suggested that inhibition of these enzymes could be potential chemothera-
peutic targets.
The trypanocidal effects of naturally occurring quinones and their derivatives 
and naphthoimidazoles derived from β-lapachone N1, N2, and N3 were the stron-
gest. To assess the molecular mechanisms of action of these compounds, researchers 
studied treated bloodstream trypomastigotes by 2D-DIGE followed by MALDI-
TOF/TOF. A total of 61 differentially abundant protein spots were identified when 
comparing the control with the N1, N2, or N3 treatment for 34 identified spots. 
The differentially abundant proteins included activated protein kinase C recep-
tor, tubulin isoforms, asparagine synthetase, arginine kinase, elongation factor 2, 
enolase, guanine deaminase, heat shock proteins, hypothetical proteins, paraflagel-
lar rod components, RAB GDP dissociation inhibitor, succinyl-CoA ligase, ATP 
synthase subunit B, and methionine sulfoxide reductase. These information allowed 
the identification of different modes of action for N1, N2, and N3, which indicate a 
great variety of metabolic pathways involved and open new avenues for the devel-
opment of new trypanocidal drugs [65].
In addition, proteomics was used to identify proteins involved in N1, N2, and N3 
trypanocidal activity. In epimastigotes, naphthoimidazoles are involved in multiple 
mechanisms: (a) redox metabolism, (b) energy production, (c) ergosterol biosyn-
thesis, (d) cytoskeleton assembly, (e) protein metabolism and biosynthesis, and 
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(f) chaperone modulation. These compounds were able to induce an imbalance in 
crucial pathways of the parasite, leading to the loss of metabolic homeostasis and T. 
cruzi death [66].
A proteomic analysis of T. cruzi resistance to Bz was reported initially by 
Andrade et al. [67]. The differential proteomes of T. cruzi with selected in vivo 
resistance to Bz (BZR and Clone27R), its susceptible pairs (BZS and Clone9S), and 
a pair from a population with benznidazole in vitro-induced resistance (17LER) 
and the susceptible pair 17WTS were studied by 2-DE followed by MS. Among 137 
spots studied through MS, 110 were detected as 56 distinct proteins. Among the 
56 different proteins, 36 were detected in resistant, 9 in susceptible, and 11 in both 
phenotypes. In the group of the proteins identified in resistant samples, five were 
found in Cl 27R and in BZR (calpain-like cysteine peptidase, hypothetical protein 
conserved 26 kDa, putative peptidase, peroxiredoxin, and tyrosine amino transfer-
ase) and four in Cl 27R and 17LER (cyclophilin A, glutamate dehydrogenase, iron 
superoxide dismutase, and nucleoside diphosphate kinase). However, the proteins 
detected in Bz-susceptible samples, PGF-2a, were found in BZS and 17WTS. A 
functional category study has shown that proteins engaged in transcription and 
protein destination were overexpressed in the Bz-resistant phenotype. This report 
provided large-scale, proteomic information to obtain a better knowledge of the 
mechanism involved in T. cruzi resistance to Bz [67].
8. Laboratory diagnostic and protein identification
Immune complexes (ICs) are the direct result of humoral immune responses. 
Therefore, the identification of foreign constituents or autoantigens within ICs 
might provide new insights into the immunopathology of infectious diseases. 
Ohyama and coworkers [68] studied the immune complexome of plasma samples 
obtained from T. cruzi-infected patients. Then, 20 seropositive plasma samples, 
including cardiac and/or megacolon chronic patients (n = 11) and asymptomatic 
patients (n = 9), were analyzed together with 10 seronegative healthy people to 
investigate the antigens linked to circulating ICs. In this study, 39 T. cruzi antigens 
and 114 human autoantigens particular to patients with Chagas disease were 
identified. In this report, two T. cruzi antigens (surface protease GP63 and glucose-
6-isomerase) and six human autoantigens (CD180 antigen, ceruloplasmin, fibrino-
gen beta chain, fibrinogen beta chain isoform 2 preprotein, isoform gamma-A of 
fibrinogen γ-chain, serum paraoxonase) were reported in more than 50% of the 
patients evaluated. Human isoforms short of complement factor H-related protein 2 
and T. cruzi TS were most often found in the asymptomatic forms of Chagas disease 
(5/9 for both) compared with the determinate Chagas (0/11, P = 0·046 for human, 
1/11, P = 0·0498 for T. cruzi). The authors conclude that the Chagas disease immune 
complexome may reflect the difference in immune status among different clinical 
stages of chronic form of T. cruzi infection [68].
In a successful translation of proteomic-based studies into accessible tools for 
bench diagnosis, Ruiz-Lancheros and coworkers [69] reported the value of apo-
lipoprotein A-1 and fibronectin fragments as markers of parasitological cure for 
congenital Chagas disease in Bz-treated children [69].
Using a proteomics approach, researchers identified a T. cruzi protein phos-
phatase 2A in a cytosolic extract previously purified in a microcystin-Sepharose 
affinity column. This strategy enables the cloning and expression of this protein 
phosphatase, which is involved in T. cruzi differentiation from trypomastigotes to 
amastigotes [70]. A proteomics approach was also used to identify a T. cruzi alfa 5 
proteasome subunit, previously recognized by the monoclonal antibody 7E5 [71].
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9. Host-parasite interaction
To investigate changes in the cells’ phosphoprotein pattern after infection, 
researchers used proteome profiler human phospho-kinase arrays to investigate the 
molecular mechanism of T. cruzi-induced alteration of the colon during the early 
infection phase of primary human colonic epithelial cells (HCoEpiCs) infected 
with T. cruzi trypomastigotes at different time points. Significant changes in the 
phosphorylation pattern that could be related to cellular deregulation in colonic epi-
thelial cells after parasite infection were observed, including a significant increase 
in the levels of phosphorylated heat shock protein (p-HSP) 27 and transcription 
factors such as c-Jun and CREB. A significant upregulation of phospho (p-) Akt 
S473 and p-JNK, which may directly or indirectly modulate CREB and c-Jun 
phosphorylation, respectively, was also observed together with increased levels of 
phosphorylated CREB and c-Jun in the nucleus. In addition, p-c-Jun and p-CREB 
colocalized in the nucleus after 180 min of T. cruzi infection. A greater level of p-c-
Jun and p-CREB has been associated with inflammatory and profibrotic responses. 
T. cruzi infection of HCoEpiCs provokes an enhanced expression of thrombos-
pondin-1 (TSP-1), which is fibrogenic at higher levels. The authors also found that 
T. cruzi infection influenced the expression of some transcription factors, such as 
NF-kB and JAK2-STAT1, which can enhance proinflammatory flux. Bioinformatics 
studies of the phosphoprotein networks derived using the phosphoprotein informa-
tion serve as a blueprint for T. cruzi-mediated cellular differentiation of HCoEpiCs 
in the lapse of the acute phase of parasite infection.
T. cruzi was shown to release vesicles containing a wide range of surface mol-
ecules to affect the host immune responses and cell invasion [72]. A proteomics 
study reported different compositions of extracellular vesicles released by two 
T. cruzi strains associated with their distinct interaction with host cells [73]. The sec-
retomes of two distinct T. cruzi strains (Y and YuYu), which were previously shown 
to differentially modulate host immune responses, were compared. Extracellular 
vesicles (EVs) obtained from tissue culture-derived trypomastigotes of both strains 
were purified and quantitated. Proteomics studies confirmed the higher concentra-
tions of proteins encoded by the trans-sialidase (TS) gene superfamily, MASPs, and 
several well-known exosomal proteins in the YuYu strain, which also have shown a 
significant difference among purified EVs and the vesicle-free fraction compared 
to the Y strain. In order to know if those differences were associated with T. cruzi 
infectivity, J774 phagocytic cells and LLC-MK2 non-phagocytic cells were previ-
ously incubated with isolated EVs from both strains and then infected with TCDTs 
from Y strain. EVs liberated by the YuYu strain provoked smaller levels of infection 
but an increased intracellular proliferation in J774 macrophages than EVs from the Y 
strain. On the other hand, YuYu strain-derived EVs induced greater levels of infec-
tion of LLC-MK2 cells than Y strain-derived EVs. In summary, the quantitative and 
qualitative differences in EVs and released proteins from distinct T. cruzi strains may 
be correlated with the parasite capacity to be infective and virulent [73].
The involvement of host cell-derived microvesicles (MVs) during the early 
interaction between T. cruzi MTs and THP-1 cells was previously demonstrated. 
To determine the contribution of different parasite stages and their extracellular 
vesicles in the interaction with host cells, researchers assessed TCDTs, MTs, and 
EPIs, which were shown to provoke distinct levels of MV liberated from THP-1 
cells. Nevertheless, only MTs and TCDTs could enhance parasite cell invasion. 
Fluorescence resonance energy transfer microscopy showed that THP-1-derived 
MVs can fuse with parasite-derived MVs. Additionally, MVs released from the 
TCT-THP-1 interaction displayed a bigger fusogenic ability than those from the 
META- or EPI-THP-1 interaction. However, by proteomics, a greater concentration 
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of proteins from MTs (25%) than TCDTs (12%) or EPIs (5%) was detected in MVs 
from the parasite-THP-1 interaction. Lastly, sera from patients with chronic Chagas 
disease at the indeterminate or cardiac phase were able to identify antigens in 
THP-1-derived MVs resulting only from interaction with META or TCDTs forms. 
Elucidation of the cellular traffic pathways and the role of MVs in modulation of 
host immune system could supply significant hints with respect to Chagas disease 
pathophysiology [74].
T. cruzi has two tryparedoxins (TcTXNI and TcTXNI) pertaining to the thiore-
doxin superfamily. TXNs are oxidoreductases that have a role in electron transfer 
between trypanothione and peroxiredoxins [75, 76]. This represents a difference 
with the mammalian cells, in which these roles are performed by thioredoxins. These 
differences make TXNs a new and interesting chemotherapeutic target. T. cruzi 
tryparedoxin 1 (TcTXN1) is a cytoplasmic and constitutively expressed protein in 
T. cruzi. To elucidate the T. cruzi redox interactome, an active-site mutant protein 
lacking the resolving cysteine was designed. Then, the in vitro complex formation 
among the mutated TcTXN1 and its natural partner, the cytoplasmic peroxiredoxin, 
was validated. By the expression of this mutant protein in parasites with an additional 
6xHis-tag, heterodisulfide complexes were purified and identified by 2-DE/MS. This 
allowed us to identify 15 TcTXN1 proteins that were involved in 2 main processes: 
oxidative metabolism and protein synthesis and degradation. This type of experiment 
allowed the discovery of several putative TcTXN1-interacting proteins and contrib-
uted to a better understanding of the redox T. cruzi interactome [77]. In another 
work, the study was extended to TcTXNII. TcTXNII is a transmembrane protein 
anchored to the mitochondria surface and endoplasmic reticulum, with a cytoplasmic 
orientation of the redox domain. This protein is expressed during the metacyclogen-
esis process. To further characterize the redox interactome of T. cruzi, an active-site 
mutant TcTXNII lacking the resolving cysteine was designed, and through the 
expression of this mutant protein and incubation with T. cruzi proteins, heterodi-
sulfide complexes were isolated and identified by mass spectrometry. This approach 
allowed the identification of 16 TcTXNII-interacting proteins that are involved in a 
wide range of cellular processes. Thus, this report indicated the relevance of TcTXNII 
and contributed to a better understanding of the T. cruzi redox interactome [77].
TcI isolates of T. cruzi exploit the antioxidant network for enhanced intracellular 
survival in macrophages and virulence in mice. In these reports, the TcI strains 
Colombiana (COL) and SylvioX10/4 (SYL) and a cultured clone (TCC) displayed 
distinct biological features in an experimental murine infection, including high 
parasitemia and symptomatic cardiomyopathy (SYL), low parasitemia and high tis-
sue tropism (COL), and no pathogenicity (TCC). A proteomic study of the EPI and 
TCDT stages by 2-DE and MALDI-TOF MS, followed by functional annotation of 
the differential proteome data sets (≥twofold change, P < 0.05) demonstrated that 
(i) many proteins were engaged in cytoskeletal assembly and remodeling essential 
for flagellar wave frequency and amplitude and forward motility of the parasite 
and (ii) the parasite-specific antioxidant network was improved in COL and SYL 
(versus TCC) trypomastigotes. Immunoblots reveal the increased protein levels of 
cytoplasmic and mitochondrial tryparedoxin peroxidases and their substrate (try-
paredoxin) and iron superoxide dismutase in COL and SYL (versus TCC) trypo-
mastigotes. In addition, COL and SYL (but not TCC) were resistant to experimental 
treatment with oxidants such as H2O2 and peroxynitrite [ONOO(−)]. These parasite 
isolates were able to resist the intracellular superoxide and nitric oxide response in 
macrophages and were not killed by them. These observations indicate that protein 
expression focused on increased motility and control of macrophage-derived free 
radicals may represent a survival and persistence strategy developed by TcI isolates 
of T. cruzi [78].
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10. T. cruzi typing
T. cruzi strains have been allocated to seven genetic groups (TcI-TcVI and TcBat), 
called discrete typing units (DTUs), which constitute groups of parasite isolates 
that differ in geographical origins, virulence, pathogenicity, and immunological 
properties [79]. In addition, several clinical manifestations (from asymptomatic to 
extremely severe illness) have been intended to be linked to T. cruzi genetic variabil-
ity. For this reason, many DTU typing approaches have been proposed. Recently, a 
T. cruzi strain typing assay using MS2 peptide spectral libraries (Tc-STAMS2) was 
developed [80]. The Tc-STAMS2 methodology used shotgun proteomics associated 
with a spectral library quest to assign and discriminate T. cruzi strains independent 
of genome information. This approach was based on the built of a library of MS/MS 
peptide spectra constructed using genotyped T. cruzi reference strains. For iden-
tification, the MS/MS peptide spectra of unheard T. cruzi isolated were identified 
by the spectral matching algorithm SpectraST. The Tc-STAMS2 approach enabled 
right identification of all DTUs with high reliance. The approach was robust toward 
distinct sample preparations, length of chromatographic gradients, and fragmenta-
tion techniques.
The Tc-STAMS2 procedure allowed T. cruzi strain typing using MS/MS spectra 
as discriminatory functions and allowed the differentiation of TcI-TcVI DTUs. 
Similar to genomic-based procedures, the Tc-STAMS2 method permits identifica-
tion of strains within DTUs. Its robustness toward different experimental and 
biological variables makes it an invaluable complementary methodology to the 
existing T. cruzi genotyping assays. Furthermore, this approach may be applied to 
identify DTU-specific properties correlated with the strain phenotype [73].
A proteomics analysis of two T. cruzi zymodeme 3 strains was also performed. 
In fact, two T. cruzi Z3 strains, designated 3663 and 4167, isolated from Brazilian 
Amazon triatomines were studied. These strains exhibited different infection 
patterns for Vero cells, in which 3663 trypomastigotes were much less infective than 
4167 trypomastigotes. By proteomics, the differences in the global protein expres-
sion profiles of these two Z3 strains were investigated. Two-dimensional (2D) pro-
tein maps were obtained, and some spots were identified by MS. The study showed 
a meaningful difference in the expression profiles of several proteins in both strains. 
One of them was cruzipain, a key virulence factor. These data were corroborated 
by flow cytometric analysis using an anti-cruzipain antibody. This difference could 
contribute to the infectivity profiles observed for each strain by in vitro assays using 
different cell lines [81].
A phylogenetic character mapping of 26 stocks of T. cruzi and 2 stocks of the 
sister taxon T. cruzi marinkellei was performed to test for possible associations 
between T. cruzi-subspecific phylogenetic diversity and levels of protein expression, 
as examined by proteomics analysis and MS. A strong correlation (P < 10(−4)) was 
observed between genetic distance, as established by multilocus enzyme electro-
phoresis, and proteomic dissimilarities estimated by proteomic Euclidian distances. 
Several proteins were found to be specifically associated with T. cruzi DTUs. This 
study explored the previously uncharacterized links between T. cruzi infraspecific 
phylogenetic diversity and gene expression [82].
11. Immune response
One major problem in developing a rational search for T. cruzi vaccine candi-
dates is the restricted information with respect to the proteins that are expressed 
by different strains, clones, and isolates included in the different parasite DTUs. 
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A proteomics study of T. cruzi trypomastigotes identified 1448 nonredundant 
proteins, of which close to 14% of the found peptidic sequences corresponded to 
surface proteins, mostly of which were GPI-anchored and associated with T. cruzi 
virulence. Immunoinformatics approaches reported a high number of peptides 
with predicted high-binding capacity for class I and class II molecules of the major 
histocompatibility complex (MHC). The many different types of proteins exposed 
on the trypomastigote surface membrane could have several consequences for 
parasite cell invasion and evasion of the immune response. Finally, a rational survey 
to identify potential T-cell epitopes that may be evaluated and validated to develop a 
prophylactic vaccine to protect against T. cruzi infection was performed [21].
T. cruzi BT proteins were immunoprecipitated using serum antibodies obtained 
from asymptomatic or cardiac (stages B1 and C) patients with different forms of the 
disease and from healthy people used as controls. Proteins recognized by sera from 
Chagas disease patients were identified and quantified by MS, and changes in the 
recognition patterns were further evaluated. Compared to asymptomatic samples, 
IgG from stage C patients mainly identify the I/6 autoantigen, whereas IgG from 
B1 patients resulted in a greater recognition of dihydrolipoamide acetyltransferase 
precursor, calpain cysteine peptidase, and two variants of CAP5.5. In this paper, 
CAP5.5 identification by human serum immunoglobulin from patients with early 
myocarditis resulted in a 23-fold abundance variation when compared to sera 
obtained from asymptomatic patients. These results strongly suggest the role of 
CAP5.5 in Chagas disease cardiomyopathy.
The lack of appropriate biomarkers to assess treatments and evolution of this 
disease is the main limitation for clinical trials and patient medical evaluation. 
Accordingly, these observations may contribute to a better comprehension of T. cruzi 
pathogenesis and to evaluating potential candidates for developing vaccine and diag-
nostic tests, in addition to the clinical applicability of suitable biomarkers for patient 
follow-up and prognosis [83].
The major protein antigens targeted by the diverse antibodies of T. cruzi-infected 
mice were studied. To detect global IgG antibody specificities, sera from infected 
mice were immunoblotted against whole T. cruzi extracts. The most immunogenic 
T. cruzi proteins were identified by proteomics using MALDI-TOF-TOF. Among 
these proteins, pyruvate phosphate dikinase, Hsp-85, and β-tubulin were recognized 
by mouse IgG as the major protein bands. The T. cruzi β-tubulin gene was cloned 
and expressed in Escherichia coli, and recombinant T. cruzi β-tubulin was used to 
immunize mice. Immunized animals increased their specific IgG reactivity and were 
protected against T. cruzi infection. These results strongly suggest that proteomics, 
used for repertoire analysis, is a valid tool to identify protective antigens that could 
be vaccine candidates to protect against T. cruzi infection [84].
12. Concluding remarks and future directions
T. cruzi infection is a major health issue in America and also in the rest of 
the world, where around 8 million people are infected by T. cruzi and the other 
28  million are exposed to the parasite infection. Even more, ~20,000 people die each 
year, mainly as a result of cardiac problem. Currently, immunoprophylactic strate-
gies have not been developed, and chemotherapy is so far from optimal, based on 
two old drugs, Nf and Bz. However, these drugs are more active in the acute form of 
Chagas disease and display several side effects.
In the last 15 years, a considerable number of proteomics studies have contrib-
uted to a better understanding of the biology and biochemistry of T. cruzi. In fact, 
the proteomes of the different life cycle stages of the parasite have been described, 
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including the proteomes of different zymodemes and different parasite DTUs. 
Using a typical experimental workflow as described in Figure 1, many different 
proteomics strategies have been reported. These allowed to determine the composi-
tion of different organelles, such as ribosomes, contractile vacuoles, reservosomes, 
and nuclear protein contents. These proteomics analyses have contributed to the 
knowledge of the products excreted/secreted by the parasite and have also allowed 
us to identify the contents of the microvesicles released by different parasite stages 
and their interaction with host cells. The study of post-translational modifications 
has also been possible and has contributed to the knowledge of parasite phos-
phorylation, glycosidation, myristoylation, SUMOylation, histone acetylation, 
and methylation. Proteomics has also helped elucidate critical biological processes, 
such as metacyclogenesis, amastigogenesis, and epimastigogenesis. The pathways 
involved in resistance to Bz and in the action mode of napthoimidazoles isolated 
from β-lapachone have been studied by proteomics approaches. Interactomics 
studies that demonstrated typing using M2 peptide spectral libraries and identifica-
tion of cure markers are also among the major achievements of proteomics in the 
research field of T. cruzi and Chagas disease. In all of these cases, special care was 
taken in sample preparation, and it was always cleaned using “Stage tip” (or other 
close related system) in order to remove sample contaminants. In some experiments 
quantitative proteomics was performed using label-free methods, while in others 
labeling was performed using iTRAQ , ICAT, SILAC, or others. In all cases, digested 
proteins were submitted to liquid chromatography systems directly interfaced to 
mass spectrophotometers (Figure 1).
Figure 1. 
Flow diagram of the main events in Trypanosoma cruzi proteomics. Qualitative and quantitative analyses 
using different parasite stages can be performed. Then, the proteins can be precipitated or separated by SDS-
PAGE. Proteins are digested, in the gel or in solution using proteases, such as trypsin and Lys C. The peptides 
are subjected to a cleaning phase, and the peptides can be labeled using techniques such as ICAT, ITRAQ , 
and SILAC or not be labeled, using label-free quantification (LFQ ). Finally, the samples are subjected to a 
ultrahigh-pressure liquid chromatography (UHPLC) associated to mass spectrometry (MS). The information 
obtained is submitted to bioinformatics analysis using software such as MaxQuant (or others), for quantitative 
proteomics analysis, and then by Andromeda to obtain the sequence of the peptides in the different databases 
and Perseus (or others) to obtain classifications, proteomics interactions, post-transductional modifications, 
and metabolic pathways.
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However, we still expect major contributions of proteomics in many aspects of 
parasite biology and in various clinical aspects. The subproteomes of acidocalci-
somes and the kinetoplast-mitochondrion complex could reveal important informa-
tion about parasite biology.
In addition, the identification of new biomarkers with diagnostic and prognostic 
value and for established cure criteria is needed, and proteomics would contribute 
to this field. In the same way, the identification and validation of new chemothera-
peutic targets to develop new and more efficient drugs and the identification of new 
potential vaccine candidates could also be an expected contribution.
Furthermore, in the future, considering the concept of “precision medicine” 
or “personalized medicine,” proteomics will offer the opportunity to characterize 
strains isolated from infected patients, identify its DTU, and define appropriate 
treatments and perhaps appropriate immunoprophylaxis. Moreover, the identifica-
tion of human sera biomarkers that allow us to predict which patients with the 
undetermined forms of Chagas disease show cardiomyopathy or digestive tract 
involvement would be a relevant contribution of clinical proteomics.
Recently, San Francisco et al. [85] reported that the in vitro invasion capacity 
and in vivo Balb/c mouse infectiveness of a highly virulent T. cruzi cell line were 
strongly reduced by parasite pretreatment with antisense oligonucleotides target-
ing trans-sialidase or complement regulatory proteins or with E64d to inhibit 
cruzipain activity. However, the parasite infectivity was not completely blocked, 
suggesting that other players, different from these proteins, could be involved in 
T. cruzi virulence. Thus, for comparison of the proteomic profiles of highly virulent 
and low-virulent cell lines of T. cruzi, the molecular bases of T. cruzi virulence 
will be established. For the T. cruzi secretome, different interactions among T. 
cruzi secreted proteins and host cell signaling pathways have been proposed [86]. 
However, the role of these proteins in virulence and modulation of the host immune 
system has not been shown experimentally. T. cruzi secretome studies and immu-
nomics analyses using acute sera of animals or infected patients in the acute phase 
of the infection would help elucidate the mechanisms that T. cruzi uses to subvert 
the host immune response.
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